Joyce M. Slingerland, MD, PhD

Director, Braman Family Breast Cancer Institute, UMSylvester Comprehensive Cancer Center
Professor of Medicine

tel: 305-243-4909
fax: 305-243-4975

For Patients

Board Certifications
American Board of Internal Medicine

Practice Locations
University of Miami Hospital/Sylvester

Languages Spoken
English

Appointments
For an appointment, please call 305-243-1542 or use our online appointment form

Education
University of Toronto, Department of Medical Biophysics
Toronto, Canada		 Ph.D. Biology 1992
Princess Margaret Hospital, Division of Oncology
Toronto, Canada		 Fellowship Medical Oncology 1988
The Wellesley Hospital
Toronto, Canada		 Chief Resident Interal Medicine 1987
Princess Margaret Hospital
Toronto, Canada		 Residency Medical Oncology 1986
Toronto Hospital (General Division), Internal Medicine
Toronto, Canada		 Resident II Internal Medicine 1985
Toronto Hospital, (General Division), Internal Medicine
Toronto, Canada		 Straight Internship Internal Medicine 1984
University of Toronto
Toronto, Canada		 M.D. Internal Medicine 1983
College de Ste-Foy
Quebec, Canada		 Diplome d’Etudes Collegiales 1977

Joyce Slingerland, MD, FRCP(C), Ph.D., Director, Braman Family Breast Cancer Institute at the University of Miami Sylvester Comprehensive Cancer Center (UMSCCC).
A native of Canada, Dr. Slingerland received her M.D. from the University of Toronto in 1983, followed by a Fellowship in Internal Medicine with the Royal College of Physicians and Surgeons in Canada. In 1987, she was certified by the American Board in Internal Medicine and in Medical Oncology by the Royal College of Physicians and Surgeons. In August of 2002, Dr. Slingerland came to the University of Miami School of Medicine as the Director of the Braman Breast Cancer Institute, Sylvester Comprehensive Cancer Center where she is working to expand and coordinate research efforts on breast cancer from many disciplines. Dr. Slingerland is also Professor of Medicine with a graduate appointment in the Department of Biochemistry and
Molecular Biology at the University of Miami, as well as a member of the senior leadership of the UMSCCC and Co-Program Leader of the UMSCCC's Molecular Oncology and Experimental Therapeutics Program. Dr. Slingerland continues her medical practice devoted entirely to breast cancer patients
at the Sylvester Comprehensive Cancer Center and the Jackson Memorial Hospital. She has published over 50 articles and reviews in addition to
several book chapters and has received numerous awards. The Slingerland's lab has been funded by the Canadian NCI's Breast Cancer Research Initiative and by the DOD Breast Cancer Research Program and now the US NCI. Her research has provided insights on how cancers escape negative growth controls. Dr. Slingerland has made the innovative discovery of the cell cycle inhibitor, p27, and showed that p27 deregulation is prognostic of
poor patient outcome and leads to antiestrogen resistance in estrogen receptor positive breast cancers.